JP2005041796A - External preparation for improving skin wrinkle prevention - Google Patents
External preparation for improving skin wrinkle prevention Download PDFInfo
- Publication number
- JP2005041796A JP2005041796A JP2003201207A JP2003201207A JP2005041796A JP 2005041796 A JP2005041796 A JP 2005041796A JP 2003201207 A JP2003201207 A JP 2003201207A JP 2003201207 A JP2003201207 A JP 2003201207A JP 2005041796 A JP2005041796 A JP 2005041796A
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- coleus
- extract
- external preparation
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【0001】
【発明の属する技術分野】
本発明は、シワ予防改善用皮膚外用剤に関する。
【0002】
【従来の技術】
シワやタルミを特徴とする皮膚の老化現象は、真皮におけるコラーゲンやヒアルロン酸合成の低下が原因の一つと考えられており、シワやタルミの改善にはビタミンAやその誘導体が広く用いられている(特許文献1、非特許文献1)。ビタミンAは皮膚の細胞に存在するレセプターを介してシワ予防改善効果を発揮すると考えられているが(非特許文献2)、紫外線を浴びた皮膚ではそのレセプターが減少しており(非特許文献3)、ビタミンAやその誘導体は十分なシワ予防改善効果を発揮することができないのが現状である。
ビタミンAレセプターの防御とは、このような紫外線によるレセプターの減少を防ぐことを意味する。ビタミンAレセプターを防御することで、ビタミンAやその誘導体のコラーゲン合成促進効果が十分に発揮され、シワやタルミが改善されると考えられる。
【0003】
【特許文献1】
特開平08−073338号
【非特許文献1】
圷信子,フレグランスジャーナル,2001,29(2),37−42
【非特許文献2】
Zoubolis C.C.,IFSCC Magagine,2000,3,9−19
【非特許文献3】
Wang Z.,Nature Medicine,1999,5,418−422
【0004】
【発明が解決しようとする課題】
そこで、紫外線によるビタミンAレセプターの減少を防ぎ、ビタミンAやその誘導体の老化防止効果が十分に得られる皮膚外用剤が求められている。
【0005】
【課題を解決するための手段】
このような事情により、本発明者らは鋭意研究を重ねた結果、コリウスの抽出物が、紫外線によるビタミンAレセプターの減少を防ぐ効果に優れ、ビタミンAやその誘導体のシワ予防改善効果を高める作用があることを見出し、本発明を完成するに至った。
【0006】
すなわち、本発明は、コリウスの抽出物を含有することを特徴とするシワ予防改善用皮膚外用剤である。
【0007】
本発明に用いるシソ科の植物としては、シソ科ソレステロン属、コリウス属などに属し、ソレノステモンスクテラリオイデス(Solenostemon scutellarioides)、コリウスブルメイ(Coleus blumei)、コリウススクテラリオイデス(Coleus scutellarioides)などがある。特に、ソレノステモンスクテラリオイデス、コリウスブルメイは園芸品種「コリウス」として広く販売されている。中でも中国で彩葉草といわれているコリウススクテラリオイデスが好ましい。
【0008】
抽出する溶媒としては、例えば、水、低級1価アルコール類(メタノール、エタノール、1−プロパノール、2−プロパノール、1−ブタノール、2−ブタノール等)、液状多価アルコール(1,3−ブチレングリコール、プロピレングリコール、グリセリン等)、ケトン類(アセトン、メチルエチルケトン等)、アセトニトリル、エステル類(酢酸エチル、酢酸ブチル等)、炭化水素類(ヘキサン、ヘプタン、流動パラフィン等)、エーテル類(エチルエーテル、テトラヒドロフラン、プロピルエーテル等)が挙げられる。好ましくは、水、エタノール、1,3−ブチレングリコールおよびプロピレングリコールが良い。これらの溶媒は一種でも二種以上を混合しても良い。
【0009】
また、コリウスの抽出物は、抽出した溶液のまま用いても良く、必要に応じて、濃縮、希釈、濾過等の処理及び活性炭等による脱色、脱臭処理をして用いても良い。さらには、抽出した溶液を濃縮乾固、噴霧乾燥、凍結乾燥等の処理を行い、乾燥物として用いても良い。
【0010】
本発明の皮膚外用剤、ビタミンAレセプター防御剤、コラーゲン合成促進剤中に配合されるコリウスの抽出物は、剤型や期待する効果の程度により異なるが、通常0.0001〜50%程度、好ましくは0.001〜10%程度配合するのがよい。0.0001%未満では十分な効果は望みにくい場合があり、50%を超えて配合した場合、効果の増強は認められにくく不経済である。また、添加の方法については、予め加えておいても、製造途中で添加して良く、作業性を考えて適宜選択すれば良い。
【0011】
本発明の皮膚外用剤、ビタミンAレセプター防御剤、コラーゲン合成促進剤は上記必須成分の他に、通常の化粧料、医薬部外品、医薬品等に用いられる各種成分、例えば油性成分、乳化剤、保湿剤、増粘剤、薬効成分、防腐剤、顔料、粉体、pH調整剤、紫外線吸収剤、抗酸化剤、香料等を適宜配合することができる。
【0012】
具体的には油性成分としては、例えば流動パラフィン、ワセリン、マイクロクリスタリンワックス、スクワラン、ホホバ油、ミツロウ、カルナウバロウ、ラノリン、オリーブ油、ヤシ油、高級アルコール、脂肪酸、高級アルコールと脂肪酸のエステル、シリコーン油等が挙げられる。乳化剤としては、例えばポリオキシエチレンアルキルエーテル、ポリオキシエチレン脂肪酸エステル、ポリオキシエチレンソルビタン脂肪酸エステル、ソルビタン脂肪酸エステル、グリセリン脂肪酸エステル、ポリグリセリン脂肪酸エステル、ポリオキシエチレン硬化ヒマシ油等の非イオン界面活性剤、ステアロイル乳酸ナトリウム等のアニオン界面活性剤、大豆リン脂質等の両性界面活性剤、塩化アルキルトリメチルアンモニウム等のカチオン界面活性剤が挙げられる。保湿剤としては、例えばグリセリン、ソルビトール、キシリトール、マルチトール、プロピレングリコール、ポリエチレングリコール、1,3−ブチレングリコールなどが挙げられる。増粘剤としては、例えばカルボキシビニルポリマー、キサンタンガム、メチルセルロース、ポリビニルピロリドン、ゼラチン、ベントナイト等の粘土鉱物等が挙げられる。薬効成分としては、例えば各種ビタミンおよびその誘導体、アラントイン、グリチルリチン酸およびその誘導体、各種動植物抽出物等が挙げられる。
【0013】
本発明のシワ予防改善用皮膚外用剤は、化粧品、医薬部外品、医薬品のいずれにも用いることができ、その剤型としては、例えば、化粧水、クリーム、乳液、ゲル剤、エアゾール剤、パップ剤、エッセンス、パック、洗浄剤、浴用剤、ファンデーション、打粉、口紅、軟膏等が挙げられる。
【0014】
【実施例】
次に本発明を詳細に説明するため、実施例として本発明に用いる抽出物の製造例、本発明の処方例及び実験例を挙げるが、本発明はこれに限定されるものではない。実施例に示す配合量は重量%を示す。
【0015】
製造例1 コリウスの熱水抽出物
コリウス(Coleus scutellarioides)の乾燥物20gに400mlの精製水を加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してコリウスの熱水抽出物を1.8g得た。
【0016】
製造例2 コリウスのエタノール抽出物
コリウス(Coleus scutellarioides)の乾燥物100gに900mlのエタノールを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、コリウスのエタノール抽出物を5.9g得た。
【0017】
製造例3 コリウスの1,3−ブチレングリコール水溶液抽出物
コリウス(Coleus scutellarioides)の乾燥物100gに1kgの精製水と1kgの1,3−ブチレングリコールを加え、常温で7日間抽出した後、濾過し、コリウスの1,3−ブチレングリコール水溶液抽出物を1.9kg得た。
【0018】
[製造方法]成分2〜10を加熱溶解して混合し、70℃に保ち油相とする。成分1および12〜15を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分11を加え、さらに30℃まで冷却して製品とする。
【0019】
比較例1 従来のクリーム
実施例1において、コリウスの熱水抽出物(製造例1)を精製水に置き換えたものを従来のクリームとした。
【0020】
[製造方法]成分1、3〜7および12と、成分2および8〜11をそれぞれ均一に溶解し、両者を混合し濾過して製品とする。
【0021】
[製造方法]成分2〜9を加熱溶解して混合し、70℃に保ち油相とする。成分1および11〜14を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分10を加え、さらに30℃まで冷却して製品とする。
【0022】
成分2〜6と、成分1および7〜12をそれぞれ均一に溶解し、両者を混合して製品とする。
【0023】
[製造方法]成分2〜6を加熱溶解して混合し、70℃に保ち油相とする。成分1および7〜9を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化し、かき混ぜながら30℃まで冷却して製品とする。
【0024】
[製造方法]成分1〜11を均一に溶解し製品とする。
【0025】
[製造方法]成分2〜10を加熱溶解し、80℃に保ち油相とする。成分21に成分11をよく膨潤させ、続いて、成分1および12〜15を加えて均一に混合する。これに粉砕機で粉砕混合した成分16〜20を加え、冷却し、45℃で成分を加え、かき混ぜながら30℃まで冷却して製品とする。
【0026】
[製造方法]成分1〜6を均一に混合し製品とする。
【0027】
次に、本発明の効果を詳細に説明するため、実験例を挙げる。
【0028】
実験例1 ビタミンAレセプター防御作用
6週齢のICRマウス背部を毛刈し、そこに紫外線A波10J/cm2を7日間連続で照射した。紫外線照射したマウスには実施例1のクリームを適量塗布し、最終照射の翌日に皮膚をサンプリングした。皮膚のビタミンAレセプターは、ウェスタンブロット法により測定を行った。操作は定められた方法(Fisher G.J.,J.Biol.Chem.,1994,269,20629−20635)に従い、タンパク抽出液をポリアクリルアミドゲル電気泳動に供し、トランスファーメンブレンにブロッティングしたレセプタータンパクを抗体染色した。すなわち、ビタミンAレセプター抗体を1μg/mlとなるように2%スキムミルクで希釈し、メンブレンを入れてハイブリバック中で37℃、2時間インキュベーションした。洗浄後、メンブレンを二次抗体となるHRP標識抗マウス抗体とともにハイブリバックに入れ、37℃で1時間インキュベーションした。洗浄したメンブレンをECLウェスタンブロッティング検出試薬に1分間浸した後、暗室下、オートラジオグラフィー用カセットにX線フィルムを入れ、その上にメンブレンを乗せて2〜10分間露光し、フィルムを現像した。このようにして得られたビタミンAレセプターのバンドをデンシトメーターを用いて定量化し、紫外線未照射時の皮膚レセプター量を100として比較した。
【0029】
結果を表1に示した。その結果、紫外線照射皮膚では明らかにビタミンAレセプターは減少したが、実施例1のクリームを塗布することによってその減少は抑えられ、コリウスにビタミンAレセプターに対する防御作用が認められた。
【0030】
【表1】
【0031】
実験例2 マウス皮膚におけるコラーゲン合成
6週齢のICRマウス背部を毛刈し、そこに紫外線A波を4週間連続で5J/cm2照射した。照射後、実施例1のクリーム、比較例1のクリームを塗布し、最終照射の翌日に皮膚をサンプリングした。皮膚コラーゲン量はヒドロキシプロリンを定量することによって行った。
【0032】
結果を表2に示した。まず、紫外線未照射のマウスにおいて、比較例1のクリームでコラーゲン合成は促進し、ビタミンAの効果を確認した。一方、紫外線照射マウスでは比較例1のビタミンAによる効果は紫外線未照射のマウスに比べて著しく減少した。これは実験例1の結果より、紫外線照射によって皮膚ビタミンAレセプターが減少したことによるものと推測された。これに対して、実施例1のクリームによるコラーゲン合成促進効果は紫外線照射マウスでも認められ、彩葉草によってビタミンAレセプターの減少が抑えられ、ビタミンAのコラーゲン合成促進効果が紫外線を照射していない場合と同じように現われた結果と思われる。
【0033】
【表2】
【0034】
コリウスブルメイ、ソレノステモンスクテラリオイデスの熱水抽出物もビタミンAレセプター防御作用、コラーゲン合成促進作用がみられた。
【0035】
実験例3 シワやタルミの改善効果
実施例1のクリーム、比較例1の従来のクリームを用いて、肌のタルミ及びシワに悩む女性20人(25〜40才)を対象に1ヶ月間の使用試験を行った。使用後、肌のタルミやシワの改善効果をアンケートにより評価した。
【0036】
【表3】
【0037】
【表4】
【0038】
実施例2〜8についても同様の試験を行い、同様の改善作用が認められた。また、皮膚トラブルもなく、安全であった。
【発明の効果】
以上のことから、本発明のコリウス抽出物は紫外線によるビタミンAレセプターの減少を防ぐことによって、ビタミンAやその誘導体のコラーゲン合成促進作用高め、これを含有することを特徴とするシワ改善用皮膚外用剤は安全性に優れ、肌に対して優れた効果を示した。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a skin external preparation for improving wrinkle prevention.
[0002]
[Prior art]
Skin aging, which is characterized by wrinkles and tarmi, is considered to be caused by a decrease in collagen and hyaluronic acid synthesis in the dermis. Vitamin A and its derivatives are widely used to improve wrinkles and tarmi. (Patent Document 1, Non-Patent Document 1). Vitamin A is thought to exert a wrinkle prevention / improvement effect through a receptor present in skin cells (Non-patent Document 2), but the receptor is reduced in skin exposed to ultraviolet rays (Non-patent Document 3). ), Vitamin A and its derivatives are not capable of exhibiting sufficient wrinkle prevention and improvement effect.
Vitamin A receptor protection means prevention of such receptor depletion by ultraviolet rays. By protecting the vitamin A receptor, the collagen synthesis promoting effect of vitamin A and its derivatives is sufficiently exerted, and wrinkles and tarmi are considered to be improved.
[0003]
[Patent Document 1]
JP 08-073338 [Non-patent Document 1]
Nobuko Tsuji, Fragrance Journal, 2001, 29 (2), 37-42
[Non-Patent Document 2]
Zoubolis C.I. C. IFSCC Magazine, 2000, 3, 9-19
[Non-Patent Document 3]
Wang Z. , Nature Medicine, 1999, 5, 418-422.
[0004]
[Problems to be solved by the invention]
Therefore, there is a need for an external preparation for skin that prevents the decrease in vitamin A receptor due to ultraviolet rays and sufficiently provides the anti-aging effect of vitamin A and its derivatives.
[0005]
[Means for Solving the Problems]
Under these circumstances, the present inventors have conducted intensive research. As a result, the extract of Coleus is excellent in preventing the decrease of vitamin A receptor due to ultraviolet rays, and enhances the wrinkle prevention and improvement effect of vitamin A and its derivatives. As a result, the present invention has been completed.
[0006]
That is, this invention is a skin external preparation for wrinkle prevention improvement characterized by containing the extract of Coleus.
[0007]
The Labiatae plant used in the present invention belongs to the genus Solesterone, Coleus, etc., and Solenostemon scutellarioides, Coleus bloomei, Coleus scutellarioides. and so on. In particular, Solenostemon scutellarioides and Coleus brumei are widely sold as horticultural varieties “Coleus”. Of these, Coleus scutellarioides, which is said to be a colored leaf grass in China, is preferable.
[0008]
Examples of the solvent to be extracted include water, lower monohydric alcohols (methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, etc.), liquid polyhydric alcohols (1,3-butylene glycol, Propylene glycol, glycerin, etc.), ketones (acetone, methyl ethyl ketone, etc.), acetonitrile, esters (ethyl acetate, butyl acetate, etc.), hydrocarbons (hexane, heptane, liquid paraffin, etc.), ethers (ethyl ether, tetrahydrofuran, Propyl ether, etc.). Water, ethanol, 1,3-butylene glycol and propylene glycol are preferable. These solvents may be used alone or in combination of two or more.
[0009]
Further, the Coleus extract may be used as it is, or may be used after treatment such as concentration, dilution, and filtration, and decolorization or deodorization treatment with activated carbon or the like, if necessary. Furthermore, the extracted solution may be subjected to a treatment such as concentration to dryness, spray drying, freeze drying, etc., and used as a dried product.
[0010]
The extract of Coleus blended in the external preparation for skin, vitamin A receptor protective agent, and collagen synthesis accelerator of the present invention varies depending on the dosage form and the expected effect, but is usually about 0.0001 to 50%, preferably Is preferably added in an amount of about 0.001 to 10%. If it is less than 0.0001%, a sufficient effect may be difficult to expect, and if it exceeds 50%, an increase in the effect is hardly recognized and it is uneconomical. In addition, the addition method may be added in advance during the production, or may be appropriately selected in consideration of workability.
[0011]
The external preparation for skin, vitamin A receptor protective agent, and collagen synthesis promoter of the present invention are various components used in normal cosmetics, quasi-drugs, pharmaceuticals, etc. in addition to the above essential components, such as oily components, emulsifiers, and moisturizing agents. Agents, thickeners, medicinal components, preservatives, pigments, powders, pH adjusters, ultraviolet absorbers, antioxidants, fragrances and the like can be appropriately blended.
[0012]
Specific examples of the oil component include liquid paraffin, petrolatum, microcrystalline wax, squalane, jojoba oil, beeswax, carnauba wax, lanolin, olive oil, coconut oil, higher alcohol, fatty acid, ester of higher alcohol and fatty acid, silicone oil, and the like. Is mentioned. Examples of the emulsifier include nonionic surfactants such as polyoxyethylene alkyl ether, polyoxyethylene fatty acid ester, polyoxyethylene sorbitan fatty acid ester, sorbitan fatty acid ester, glycerin fatty acid ester, polyglycerin fatty acid ester, and polyoxyethylene hydrogenated castor oil. And anionic surfactants such as sodium stearoyl lactate, amphoteric surfactants such as soybean phospholipid, and cationic surfactants such as alkyltrimethylammonium chloride. Examples of the humectant include glycerin, sorbitol, xylitol, maltitol, propylene glycol, polyethylene glycol, 1,3-butylene glycol and the like. Examples of the thickening agent include clay minerals such as carboxyvinyl polymer, xanthan gum, methyl cellulose, polyvinyl pyrrolidone, gelatin, and bentonite. Examples of medicinal ingredients include various vitamins and derivatives thereof, allantoin, glycyrrhizic acid and derivatives thereof, and various animal and plant extracts.
[0013]
The skin external preparation for wrinkle prevention improvement of the present invention can be used for any of cosmetics, quasi-drugs, and pharmaceuticals. Examples of the dosage form include skin lotions, creams, emulsions, gels, aerosols, Examples include poultices, essences, packs, cleaning agents, bath preparations, foundations, dusting powders, lipsticks, ointments and the like.
[0014]
【Example】
Next, in order to describe the present invention in detail, examples of producing the extract used in the present invention, formulation examples and experimental examples of the present invention will be given as examples, but the present invention is not limited thereto. The compounding amount shown in the examples indicates% by weight.
[0015]
Production Example 1 Coleus hot water extract 400 g of purified water was added to 20 g of dried Coleus scutellarioides, extracted at 95-100 ° C. for 2 hours, filtered, and the filtrate was concentrated and freeze-dried. 1.8 g of hot water extract of Coleus was obtained.
[0016]
Production Example 2 Coleus ethanol extract 900 g of ethanol was added to 100 g of dried Coleus scutellarioides, extracted at room temperature for 7 days, filtered, the filtrate was concentrated to dryness, and the Coleus ethanol extract was obtained. 5.9 g was obtained.
[0017]
Production Example 3 Coleus 1,3-butylene glycol aqueous extract 1 kg of purified water and 1 kg of 1,3-butylene glycol were added to 100 g of a dried product of Coleus scutellarioides, extracted at room temperature for 7 days, and then filtered. 1.9 kg of a 1,3-butylene glycol aqueous solution extract of Coleus was obtained.
[0018]
[Manufacturing method] Components 2 to 10 are dissolved by heating and mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1 and 12 to 15 are dissolved by heating and mixed, and kept at 75 ° C. to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring.
[0019]
Comparative Example 1 A conventional cream obtained by replacing the hot water extract of Coleus (Production Example 1) with purified water in Example 1 of the conventional cream was used.
[0020]
[Production method] Components 1, 3 to 7 and 12 and components 2 and 8 to 11 are uniformly dissolved, and both are mixed and filtered to obtain a product.
[0021]
[Manufacturing method] Components 2 to 9 are heated and dissolved and mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1 and 11-14 are dissolved by heating and mixed, and kept at 75 ° C. to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring. The component 10 is added at 45 ° C., and further cooled to 30 ° C. to obtain a product.
[0022]
Ingredients 2-6 and ingredients 1 and 7-12 are uniformly dissolved, and both are mixed to obtain a product.
[0023]
[Manufacturing method] Components 2 to 6 are dissolved by heating and mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1 and 7 to 9 are dissolved by heating and mixed, and kept at 75 ° C. to obtain an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the product is cooled to 30 ° C. with stirring to obtain a product.
[0024]
[Production Method] Components 1 to 11 are uniformly dissolved to obtain a product.
[0025]
[Manufacturing method] Components 2 to 10 are heated and dissolved and kept at 80 ° C to obtain an oil phase. Ingredient 21 is well swollen in ingredient 21, then ingredients 1 and 12-15 are added and mixed uniformly. To this, components 16 to 20 pulverized and mixed with a pulverizer are added, cooled, the components are added at 45 ° C., and cooled to 30 ° C. with stirring to obtain a product.
[0026]
[Production Method] Components 1 to 6 are uniformly mixed to obtain a product.
[0027]
Next, experimental examples will be given to explain the effects of the present invention in detail.
[0028]
Experimental Example 1 Vitamin A receptor protective action The back of a 6-week-old ICR mouse was shaved and irradiated with ultraviolet A wave 10 J / cm 2 for 7 consecutive days. An appropriate amount of the cream of Example 1 was applied to the mice irradiated with ultraviolet rays, and the skin was sampled the day after the final irradiation. Skin vitamin A receptor was measured by Western blotting. In accordance with a predetermined method (Fisher GJ, J. Biol. Chem., 1994, 269, 20629-20635), the protein extract was subjected to polyacrylamide gel electrophoresis, and the receptor protein blotted on the transfer membrane was removed. Antibody staining. That is, the vitamin A receptor antibody was diluted with 2% skim milk so as to be 1 μg / ml, and a membrane was added and incubated in a hybrid bag at 37 ° C. for 2 hours. After washing, the membrane was placed in a hybrid bag together with an HRP-labeled anti-mouse antibody as a secondary antibody and incubated at 37 ° C. for 1 hour. The washed membrane was immersed in an ECL western blotting detection reagent for 1 minute, and then an X-ray film was placed in an autoradiography cassette in a dark room. The membrane was placed on the X-ray film, and exposed for 2 to 10 minutes to develop the film. The band of vitamin A receptor thus obtained was quantified using a densitometer, and the amount of skin receptor when not irradiated with ultraviolet light was compared to 100.
[0029]
The results are shown in Table 1. As a result, the vitamin A receptor was clearly decreased in the ultraviolet-irradiated skin, but the decrease was suppressed by applying the cream of Example 1, and a protective effect against vitamin A receptor was observed in Coleus.
[0030]
[Table 1]
[0031]
Experimental Example 2 Collagen synthesis in mouse skin The back of a 6-week-old ICR mouse was shaved and irradiated with ultraviolet A waves at 5 J / cm 2 for 4 consecutive weeks. After the irradiation, the cream of Example 1 and the cream of Comparative Example 1 were applied, and the skin was sampled the day after the final irradiation. The amount of skin collagen was determined by quantifying hydroxyproline.
[0032]
The results are shown in Table 2. First, collagen synthesis was promoted with the cream of Comparative Example 1 in mice not irradiated with ultraviolet rays, and the effect of vitamin A was confirmed. On the other hand, the effect of vitamin A in Comparative Example 1 was significantly reduced in the ultraviolet-irradiated mice compared to the mice not irradiated with ultraviolet rays. From the results of Experimental Example 1, this was presumed to be due to a decrease in skin vitamin A receptor by ultraviolet irradiation. On the other hand, the collagen synthesis promoting effect by the cream of Example 1 was also observed in the ultraviolet-irradiated mice, and the decrease in vitamin A receptor was suppressed by the Aya leaves, and the collagen synthesis promoting effect of vitamin A was not irradiated with ultraviolet rays. The result appears to be the same as the case.
[0033]
[Table 2]
[0034]
The hot water extract of Coleus brumei and Solenostemon scutellarioides also showed vitamin A receptor defense action and collagen synthesis promotion action.
[0035]
Experimental Example 3 Wrinkle and Talmi Improvement Effect Using the cream of Example 1 and the conventional cream of Comparative Example 1 for one month for 20 women (25 to 40 years old) suffering from skin talmi and wrinkles A test was conducted. After use, the skin tarmi and wrinkle improvement effects were evaluated by a questionnaire.
[0036]
[Table 3]
[0037]
[Table 4]
[0038]
The same test was performed on Examples 2 to 8, and the same improvement effect was recognized. Moreover, there was no skin trouble and it was safe.
【The invention's effect】
From the above, the Coleus extract of the present invention enhances the collagen synthesis promoting action of vitamin A and its derivatives by preventing the decrease of vitamin A receptor by ultraviolet rays, and contains the same for external use for improving wrinkles. The agent was excellent in safety and showed an excellent effect on the skin.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003201207A JP4485154B2 (en) | 2003-07-24 | 2003-07-24 | Skin external preparation for wrinkle prevention improvement |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003201207A JP4485154B2 (en) | 2003-07-24 | 2003-07-24 | Skin external preparation for wrinkle prevention improvement |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005041796A true JP2005041796A (en) | 2005-02-17 |
JP4485154B2 JP4485154B2 (en) | 2010-06-16 |
Family
ID=34261370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003201207A Expired - Lifetime JP4485154B2 (en) | 2003-07-24 | 2003-07-24 | Skin external preparation for wrinkle prevention improvement |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4485154B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005053798A (en) * | 2003-08-04 | 2005-03-03 | Nonogawa Shoji Kk | Fibronectin production promoter |
JP2005053797A (en) * | 2003-08-04 | 2005-03-03 | Nonogawa Shoji Kk | Collagen production promoter and collagen cross-link formation inhibitor |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001139484A (en) * | 1999-11-16 | 2001-05-22 | Lion Corp | Dermal agent for external use |
-
2003
- 2003-07-24 JP JP2003201207A patent/JP4485154B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001139484A (en) * | 1999-11-16 | 2001-05-22 | Lion Corp | Dermal agent for external use |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005053798A (en) * | 2003-08-04 | 2005-03-03 | Nonogawa Shoji Kk | Fibronectin production promoter |
JP2005053797A (en) * | 2003-08-04 | 2005-03-03 | Nonogawa Shoji Kk | Collagen production promoter and collagen cross-link formation inhibitor |
Also Published As
Publication number | Publication date |
---|---|
JP4485154B2 (en) | 2010-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005306850A (en) | Antidermopathic agent and skin lotion containing the same | |
JP2003300858A (en) | Skin care preparation | |
JP2009029734A (en) | External preparation for skin | |
JP3557095B2 (en) | Melanin production inhibitor | |
JP2003192566A (en) | Cosmetic | |
JP4880233B2 (en) | Anti-dermatological agent and external preparation for skin containing the same | |
JP4933768B2 (en) | Anti-dermatological agent and external preparation for skin containing the same | |
JP2003095858A (en) | Skin care preparation | |
JP2003192528A (en) | Cosmetic | |
JP4824181B2 (en) | Topical skin preparation | |
JP5154835B2 (en) | Whitening cosmetics | |
KR20210001045A (en) | A cosmetic composition having prevention of lipid peroxidation, improved damaged skin and soothing effect on redness of skin | |
JP4485154B2 (en) | Skin external preparation for wrinkle prevention improvement | |
JP2004345969A (en) | Tyrosinase inhibitor and bleaching cosmetic using the same | |
JP2003192567A (en) | Cosmetic | |
JP2008255043A (en) | Skincare preparation for external use | |
JP5000964B2 (en) | Testosterone 5α-reductase activity inhibitor, androgen receptor antagonist, use thereof, and method for suppressing androgen activity expression | |
JP2000143491A (en) | Cosmetic for caring aging | |
JP2001114664A (en) | Cosmetic | |
JP5415216B2 (en) | Topical skin preparation | |
JP5468866B2 (en) | Topical skin preparation | |
JP3919250B2 (en) | Wrinkle formation inhibitor | |
JP2007302704A (en) | External preparation for skin and skin-bleaching agent | |
JP4113518B2 (en) | TGF-β production promoter for suppressing hair growth of body hair | |
JP2010241715A (en) | Neutral endopeptidase inhibitor and hair growth inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20041117 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060511 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091020 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091209 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100224 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100323 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100324 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4485154 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130402 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140402 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |